Iovance Biotherapeutics, Inc. (IOVA) experienced a significant pre-market surge of 5.29% on Wednesday, indicating strong investor interest ahead of the regular trading session.
The sharp increase appears to be driven by positive analyst coverage, with Barclays maintaining a Buy rating on the stock and setting a price target of $11.00. This endorsement from a major financial institution likely boosted investor confidence in the biotechnology company's prospects.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments